Some long-awaited market innovation may help to boost declining individual CI sales in the immediate future but will it be enough to survive the credit crisis, asks Peter Carvill Click here to download pdf (PDF, 2.5MB)
For an industry where progression is not generally considered its most prolific feature, the individual critical illness (CI) sector of the market has spent the last year steadfastly, repeatedly and routinely bucking this stereotype. Since most reading this have a vested interest in a successful CI market, 2008 should hopefully be seen in future years as the point at which the product turned and started to improve. After all, in rehab, reaching rock-bottom is the first step on the road to recovery. That is the optimistic view. The opposite applies in the short term. According to Swiss R...
To continue reading this article...
Join Professional Adviser for free
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes